PLA2G7 Antikörper (AA 301-441)

Produktnummer ABIN686722

Produktdetails anti-PLA2G7 Antikörper

Target: PLA2G7 (Lp-PLA2) (Lipoprotein-Associated phospholipase A2 (Lp-PLA2))

Bindungsspezifität: AA 301-441

Reaktivität: Human, Maus, Ratte, Schwein, Kaninchen

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PLA2G7 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Kreuzreaktivität: Human, Maus, Schwein, Kaninchen, Ratte

Homologie: Dog

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human PAFAH2

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Referenzen für anti-PLA2G7 Antikörper (ABIN686722)

Han, Wang, Zhang, Liu, Li, Wang, Song, Pang, Ouyang, Tang: "Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NF?B pathways." in: Biology open, Vol. 4, Issue 5, pp. 661-5, (2015) (PubMed).

Wang, Ji, Li, Han, Guo, Song, Quan, Wang, Han, Pang, Ouyang, Tang: "Nitro-oleic acid downregulates lipoprotein-associated phospholipase A2 expression via the p42/p44 MAPK and NF?B pathways." in: Scientific reports, Vol. 4, pp. 4905, (2014) (PubMed).

Rosing, Fobker, Kannenberg, Gunia, DellAquila, Kwiecien, Stypmann, Nofer: "Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients." in: Atherosclerosis, Vol. 230, Issue 1, pp. 164-70, (2013) (PubMed).

Details zu PLA2G7

Target: PLA2G7 (Lp-PLA2) (Lipoprotein-Associated phospholipase A2 (Lp-PLA2))

Andere Bezeichnung: PAFAH (Lp-PLA2 Produkte)

Synonyme: LDL-PLA2 antikoerper, LP-PLA2 antikoerper, PAFAD antikoerper, PAFAH antikoerper, Lp-PLA2 antikoerper, PAF-AH antikoerper, R75400 antikoerper, zgc:77563 antikoerper, phospholipase A2 group VII antikoerper, phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) antikoerper, PLA2G7 antikoerper, Pla2g7 antikoerper, pla2g7 antikoerper

Hintergrund:

Synonyms: PAFAD, PAFAH, LP-PLA2, LDL-PLA2, Platelet-activating factor acetylhydrolase, PAF acetylhydrolase, 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycerophosphocholine esterase, Group-VIIA phospholipase A2, gVIIA-PLA2, LDL-associated phospholipase A2, LDL-PLA(2), PAF 2-acylhydrolase, PLA2G7

Background: Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids.

Gen-ID: 7941

UniProt: Q13093

Pathways: Peptide Hormone Metabolism